Simone Mandigers’ Post

In this white paper from the Eradigm Consulting archives, Co-founder and Senior Partner Patrick R. describes the role that cross-portfolio CI in adding value across the pharma strategy ecosystem. 👉 Why is a cross-portfolio approach to competitive intelligence important now? 👉 Where can a cross-portfolio CI function begin to seek new opportunities for competitive advantage? 👉 How is it established and deployed? 👉 What are the biggest challenges to succeed? Access the article here: https://lnkd.in/evZd5UHW

🔬 Join GLG for a Teleconference on value creation and industry dynamics in speciality pharma 🌟 🌐 GLG expert, Dr Rainer Wulf will guide us through: 🔬 Decoding the specialty pharma business model: learn how this distinctive model drives M&A strategies and cultivates brand value. 🏆 Key players on the field: we'll explore competitive differentiation and effective market positioning. 📊 Navigating the commercial landscape: gain insights into supply chain management, cost control, manufacturing efficiency, and the intricacies of logistics. 💎 The value proposition puzzle: discover how the value proposition of specialty pharma is shaped by the ever-changing market dynamics. Reserve your spot: https://lnkd.in/eurTvZEs Not a client? Get in touch: https://lnkd.in/eEbyV2Kk #GLG #SpecialityPharma #ExpertNetwork

🔬 Join GLG for a Teleconference on value creation and industry dynamics in speciality pharma 🌟 🌐 GLG expert, Dr Rainer Wulf will guide us through: 🔬 Decoding the specialty pharma business model: learn how this distinctive model drives M&A strategies and cultivates brand value. 🏆 Key players on the field: we'll explore competitive differentiation and effective market positioning. 📊 Navigating the commercial landscape: gain insights into supply chain management, cost control, manufacturing efficiency, and the intricacies of logistics. 💎 The value proposition puzzle: discover how the value proposition of specialty pharma is shaped by the ever-changing market dynamics. Reserve your spot: https://lnkd.in/eurTvZEs Not a client? Get in touch: https://lnkd.in/eEbyV2Kk #GLG #SpecialityPharma #ExpertNetwork #consulting

🔬 Join GLG for a Teleconference on value creation and industry dynamics in speciality pharma 🌟 🌐 GLG expert, Dr Rainer Wulf will guide us through: 🔬 Decoding the specialty pharma business model: learn how this distinctive model drives M&A strategies and cultivates brand value. 🏆 Key players on the field: we'll explore competitive differentiation and effective market positioning. 📊 Navigating the commercial landscape: gain insights into supply chain management, cost control, manufacturing efficiency, and the intricacies of logistics. 💎 The value proposition puzzle: discover how the value proposition of specialty pharma is shaped by the ever-changing market dynamics. Reserve your spot: https://lnkd.in/eurTvZEs Not a client? Get in touch: https://lnkd.in/eEbyV2Kk #GLG #SpecialityPharma #ExpertNetwork

🔬 Join GLG for a Teleconference on value creation and industry dynamics in speciality pharma 🌟 🌐 GLG expert, Dr Rainer Wulf will guide us through: 🔬 Decoding the specialty pharma business model: learn how this distinctive model drives M&A strategies and cultivates brand value. 🏆 Key players on the field: we'll explore competitive differentiation and effective market positioning. 📊 Navigating the commercial landscape: gain insights into supply chain management, cost control, manufacturing efficiency, and the intricacies of logistics. 💎 The value proposition puzzle: discover how the value proposition of specialty pharma is shaped by the ever-changing market dynamics. Reserve your spot: https://lnkd.in/eurTvZEs Not a client? Get in touch: https://lnkd.in/eEbyV2Kk #GLG #SpecialityPharma #ExpertNetwork

“Quality has become a strategic differentiator when it comes to stock market performance.” - Dr. Florian Zischka, Senior Manager at Deloitte. We were thrilled to host Florian at the Smart Quality Summit 2023, where he delivered an enlightening session on 'How quality in MedTech has become a catalyst for financial success.' Florian's daily role involves providing support to life sciences clients in their regulatory transformations. Prior to his journey with Deloitte, he held pivotal operational and strategic positions in the pharmaceutical industry, gaining extensive experience in quality management and culture. Get your notepads ready because we're about to unveil the crucial insights from his session! 📌Low-quality performance can significantly impact stock market results. 📌The monitoring of quality systems, like CAPA, can serve as early indicators of potential quality issues. 📌Quality management should revolve around the key design principle of risk, rather than mere compliance. If you think others could benefit from these insights, spread the word! Missed our Smart Quality Summit? No worries! You can now enjoy this masterclass at your convenience >> https://bit.ly/47wjbaR #SmartQualitySummit2023 #Quality #Compliance #LifeSciences

“36% of life sciences respondents expect the economy and inflation will continue to influence their strategy in 2024.” – Deloitte What other changes are predicted for the Biopharma industry in 2024? From navigating market competition and inflation to boosting R&D investments, embracing diversity, equity, and inclusion (DEI), and tackling supply chain challenges. These shifts are set to redefine manufacturing practices and processes across the biopharma landscape. Learn more about Biopharma trends in our latest blog : https://hubs.li/Q02r1T4R0 #Biopharma #LifeSciences #Manufacturing #PPM #DigitalTransformation

UPDATE: For anybody who hasn't received the link: https://bit.ly/3rnskTH. 💸 Essential Template for Biopharma Financial Performance Evaluation & Forecasting 💸 Biopharma companies navigate a labyrinth of challenges, from complex regulatory hurdles to the high costs of R&D. Evaluating and forecasting their financial performance isn't just advisable—it's imperative. Key elements to keep in mind: 👉🏼 R&D Investment Analysis > Gauge the scale of R&D expenditures within realistic timelines > Measure the ROI to assess long-term viability 👉🏼 Revenue Streams and Market Potential > Understand current revenue sources and market reach > Examine product pipelines, market demand, and competitive landscape 👉🏼 Risk Assessment > Recognize inherent risks in drug development > Anticipate setbacks through robust risk analysis Forecasting in biopharma isn't just numerical - it involves predicting the future impact of clinical trials, regulatory outcomes, and market shifts. I am sharing a template created by Matt Evans for financial analysis and forecasting, utilizing ratios, industry benchmarks, and trend line graphs. 👇 Want Access? Leave a comment saying 'Financial Performance' below, and I'll send it your way. Make sure we're connected so you can receive this valuable resource! #biopharma #biotech #financials #FinancialForecasting

The 12th EY M&A Firepower report has revealed a 34% surge in spending for 2023, with the total surpassing $200 billion benchmark we consider to be a healthy year. As we step into 2024, it's evident that the sector is resuming big dealmaking with the secular trends encouraging large pharma facing LOEs to replenish their pipeline. Find the latest on Lifesciences and Deal Making.

Looking to outpace your competitors? Let's talk with the experts at North Highland, our Silver Partner for the Pharma PPM Toolbox Conference, led by Helen Baxter, VP of Life Sciences & Healthcare EMEA. Discover how they can accelerate your company's growth. We are convinced that as leaders in transforming businesses with services in organizational optimization and data and systems modernization, they have the perfect #solution for your company too. Don't miss the chance to elevate your #business with North Highland at the conference. #pharmappmtoolbox #pharma #projectmanagement  #ebcg #changemanagement #pmi #pharmappm #portfoliomanagement